Screener
Summit Therapeutics SMMT Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShortTermInvestments.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $106,515 | $225,266 |
| Restricted cash | 316 | 316 |
| Short-term investments | 492,216 | 488,182 |
| Prepaid expenses and other current assets | 17,551 | 6,537 |
| Total current assets | 616,598 | 720,301 |
| Non-current assets: | ||
| Property and equipment, net | 1,664 | 1,059 |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's short-term investments?
- Summit Therapeutics (SMMT) reported short-term investments of $492.22M in Q1 2026.
- How has Summit Therapeutics's short-term investments changed year-over-year?
- Summit Therapeutics's short-term investments increased by 228.6% year-over-year, from $149.79M to $492.22M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Summit Therapeutics's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude